Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC

This article was originally published in PharmAsia News

Executive Summary

Partners Amgen and Takeda have pinned near-term oncology growth prospects on motesanib, a vascular endothelial growth factor inhibitor for the treatment of non-small cell lung cancer. Now motesanib is facing a setback; Amgen announced Nov. 19 that the Phase III MONET-1 study has been temporarily suspended after a planned safety review showed earlier mortality rates in the treatment group
Advertisement

Related Content

Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC
Bayer/Onyx’s Nexavar Falters In Lung-Cancer Phase III
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Makes $1 Billion Move For Amgen Development Rights
Takeda Makes $1 Billion Move For Amgen Development Rights
Advertisement
UsernamePublicRestriction

Register

SC067219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel